Leukotrienes are derived from arachidonic acid, the precursor of prostaglandins. There are two families of leukotrienes. The first group of leukotrienes act primarily in conditions in which inflammation is dependent on neutrophils, such as cystic fibrosis, inflammatory bowel disease, and psoriasis. The second group (cysteinyl-leukotrienes) is concerned primarily with eosinophil and mast cell induced bronchoconstriction in asthma. They bind to highly selective receptors on bronchial smooth muscle and other airway tissue. Drugs have now been designed which can interfere with the activity of leukotrienes.

 

 

Leukotriene E4 (LTE4)

 

Leukotriene Assays by LC/MS/MS

 

Matrix: Urine (2 mL urine cup) SHIP FROZEN

 

Leukotriene E4 (LTE4)

CAS 75715-89-8

LTE4 is one of the cysteinyl leukotrienes along with leukotriene C4 (LTC4) and leukotriene D4 (LTD4). The combined activity of these three leukotrienes was previously termed slow-reacting substance of anaphylaxis, or SRS-A. Unlike LTC4 and LTD4, LTE4 accumulates in both plasma and urine, therefore, urinary excretion of LTE4 is most often used as an indicator of asthma and other diseases. Cysteinyl-leukotrienes have a clear role in pathophysiological conditions such as asthma and allergic rhinitis (AR), and have been implicated in other inflammatory conditions including cardiovascular diseases, cancer, atopic dermatitis, urticaria and end-stage renal disease.

 

LTE4 is the first leukotriene assay developed by KS utilizing LC/MS/MS methodology in a urine matrix. 

 

For further inquiries concerning KS assays for leukotriene assays, click here.